Skip to content

Efficacy of Prontosan Solution on Chronic Ulcers

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01333670
Enrollment
289
Registered
2011-04-12
Start date
2011-04-30
Completion date
2012-12-31
Last updated
2014-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Wound Care, Pressure Ulcer, Wound Cleansing

Brief summary

The purpose of this study is to evaluate the efficacy of Prontosan® Wound Irrigation Solution compared with standard isotonic solution on infammation reduction and wound bed cleansing of chronic pressure or vascular leg ulcers.

Interventions

DRUGIsotonic solution (saline or lactated ringer)

* cleansing wound bed at change with isotonic solution (syringe 20-30 ml, needle 19-20 G) * positioning of sterile gauze dressing impregnated with isotonic solution on the wound for 10 minutes * dressing with isotonic solution

* cleansing wound bed at change with Prontosan Wound Irrigation solution (syringe 20-30 ml, needle 19-20 G) * positioning of sterile gauze dressing impregnated with Prontosan Wound Irrigation solution on the wound for 10 minutes * dressing with Prontosan Wound Irrigation solution

Sponsors

B. Braun Medical SA
CollaboratorINDUSTRY
Associazione Infermieristica per lo studio delle Lesioni Cutanee
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male and females aged at least 18 with Pressure ulcer stage 2-3 NPUAP (National Pressure Ulcer Advisory Panel 1989)or subcutaneous vascular ulcer with inflammation and/or biofilm and/or slough * Braden index at baseline\>=10 * Ulcer area\<80 cm2 * Ability to give an informed consent

Exclusion criteria

* Braden index at baseline\<10 * Current therapy with corticosteroids or immunosuppressor or radiotherapy * Sensitivity to any of the components of Prontosan® Solution * Diabetic foot ulcer * Current use of local antiseptics on the wound bed * Previous recruitment of another ulcer in the trial

Design outcomes

Primary

MeasureTime frame
Reduction of necrotic tissue (Pressure Sore Status Tool-PSST)From basaline visit to the final visit, that is between a minimum of 1 visit (10 days later) or a maximum of 4 visits (1 month later, weekly)
Reduction of inflammatory tissue(Pressure Sore Status Tool-PSST)From basaline visit to the final visit, that is between a minimum of 1 visit (10 days later) or a maximum of 4 visits (1 month later, weekly)

Secondary

MeasureTime frame
Frequency of wound dressing (clinical score)From basaline visit to the final visit, that is between a minimum of 1 visit (10 days later) or a maximum of 4 visits (1 month later, weekly)

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026